1. Home
  2. AMTB vs VTYX Comparison

AMTB vs VTYX Comparison

Compare AMTB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$20.41

Market Cap

776.2M

Sector

Finance

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.23

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
VTYX
Founded
1979
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
776.2M
713.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AMTB
VTYX
Price
$20.41
$8.23
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$21.75
$14.60
AVG Volume (30 Days)
239.0K
1.4M
Earning Date
01-21-2026
11-06-2025
Dividend Yield
1.75%
N/A
EPS Growth
N/A
N/A
EPS
1.59
N/A
Revenue
$388,504,000.00
N/A
Revenue This Year
$61.42
N/A
Revenue Next Year
$2.10
N/A
P/E Ratio
$12.90
N/A
Revenue Growth
51.98
N/A
52 Week Low
$15.62
$0.78
52 Week High
$24.40
$10.55

Technical Indicators

Market Signals
Indicator
AMTB
VTYX
Relative Strength Index (RSI) 60.61 46.58
Support Level $19.27 $8.61
Resistance Level $20.78 $9.30
Average True Range (ATR) 0.43 0.64
MACD -0.08 -0.10
Stochastic Oscillator 72.47 46.94

Price Performance

Historical Comparison
AMTB
VTYX

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: